Protocol Details
Collection of Blood from Patients with Prostate Cancer
This study is currently recruiting participants.
Summary
Number | 07-C-0100 |
Sponsoring Institute | National Cancer Institute (NCI) |
Recruitment Detail | Type: Participants currently recruited/enrolled
Gender: Male
Min Age: 18 Years
Max Age: N/A |
Referral Letter Required | Yes |
Population Exclusion(s) | Children |
Keywords | Genetic;
Prostatic Neoplasms;
Genotyping;
Venipuncture;
Polymorphism;
Natural History |
Recruitment Keyword(s) | Prostate Cancer |
Condition(s) | Cancer Of Prostate;
Prostate Cancer;
Prostatic Neoplasms;
Metastatic Prostate Cancer;
Prostate |
Investigational Drug(s) | None |
Investigational Device(s) | None |
Intervention(s) | None |
Supporting Site | National Cancer Institute |
Background:
-It is not fully understood why prostate cancer in some men becomes androgen-independent (no longer responds to anti-androgen medication), but genetics likely plays an important role.
-Genes contain the hereditary information that is passed down from parents to children. Although everyone has the same set of genes, individuals can have different forms of the same gene.
-Differences in genes may explain, at least in part, why some people develop a more aggressive form of prostate cancer than others.
Objectives:
-To obtain blood samples from patients with prostate cancer to try to identify gene differences associated with progression to the androgen independent state.
Eligibility:
-All participants participating in NCI prostate cancer protocols.
Design:
-Participants with prostate cancer are evaluated in the NCI s Medical Oncology Clinic.
-Blood samples are collected at the initial visit or at follow-up visits.
-DNA (genetic material) and white blood cells are extracted from these samples to be used for genotyping and establishment of cell lines.
-Gene variations are correlated with prostate cancer prognosis and prognostic indicators.
Eligibility
INCLUSION CRITERIA: Individuals 18 years of age and older are eligible.
Individuals with a diagnosis of prostate cancer are eligible.
EXCLUSION CRITERIA:
Children are not eligible.
Citations:
Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM Jr, Bueschen AJ, Lowe BA. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998 Oct 8;339(15):1036-42. Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol. 1985 Jun;3(6):827-41. Ruijter E, van de Kaa C, Miller G, Ruiter D, Debruyne F, Schalken J. Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev. 1999 Feb;20(1):22-45.
Contacts:
Clinical Trials Number:
NCT00923221Protocol Details
Collection of Blood from Patients with Prostate Cancer
This study is currently recruiting participants.
Summary
Number | 07-C-0100 |
Sponsoring Institute | National Cancer Institute (NCI) |
Recruitment Detail | Type: Participants currently recruited/enrolled
Gender: Male
Min Age: 18 Years
Max Age: N/A |
Referral Letter Required | Yes |
Population Exclusion(s) | Children |
Keywords | Genetic;
Prostatic Neoplasms;
Genotyping;
Venipuncture;
Polymorphism;
Natural History |
Recruitment Keyword(s) | Prostate Cancer |
Condition(s) | Cancer Of Prostate;
Prostate Cancer;
Prostatic Neoplasms;
Metastatic Prostate Cancer;
Prostate |
Investigational Drug(s) | None |
Investigational Device(s) | None |
Intervention(s) | None |
Supporting Site | National Cancer Institute |
Background:
-It is not fully understood why prostate cancer in some men becomes androgen-independent (no longer responds to anti-androgen medication), but genetics likely plays an important role.
-Genes contain the hereditary information that is passed down from parents to children. Although everyone has the same set of genes, individuals can have different forms of the same gene.
-Differences in genes may explain, at least in part, why some people develop a more aggressive form of prostate cancer than others.
Objectives:
-To obtain blood samples from patients with prostate cancer to try to identify gene differences associated with progression to the androgen independent state.
Eligibility:
-All participants participating in NCI prostate cancer protocols.
Design:
-Participants with prostate cancer are evaluated in the NCI s Medical Oncology Clinic.
-Blood samples are collected at the initial visit or at follow-up visits.
-DNA (genetic material) and white blood cells are extracted from these samples to be used for genotyping and establishment of cell lines.
-Gene variations are correlated with prostate cancer prognosis and prognostic indicators.
Eligibility
INCLUSION CRITERIA: Individuals 18 years of age and older are eligible.
Individuals with a diagnosis of prostate cancer are eligible.
EXCLUSION CRITERIA:
Children are not eligible.
Citations:
Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM Jr, Bueschen AJ, Lowe BA. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998 Oct 8;339(15):1036-42. Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol. 1985 Jun;3(6):827-41. Ruijter E, van de Kaa C, Miller G, Ruiter D, Debruyne F, Schalken J. Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev. 1999 Feb;20(1):22-45.
Contacts:
Clinical Trials Number:
NCT00923221